CN106714556B - 用于测定自闭症谱系病症风险的方法和系统 - Google Patents

用于测定自闭症谱系病症风险的方法和系统 Download PDF

Info

Publication number
CN106714556B
CN106714556B CN201580028014.7A CN201580028014A CN106714556B CN 106714556 B CN106714556 B CN 106714556B CN 201580028014 A CN201580028014 A CN 201580028014A CN 106714556 B CN106714556 B CN 106714556B
Authority
CN
China
Prior art keywords
asd
metabolites
acid
metabolite
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580028014.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106714556A (zh
Inventor
U·盖根穆勒
D·达米安
M·帕库拉
M·A·德普里斯托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/493,141 external-priority patent/US20150294081A1/en
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Priority to CN202110060437.4A priority Critical patent/CN113009122B/zh
Publication of CN106714556A publication Critical patent/CN106714556A/zh
Application granted granted Critical
Publication of CN106714556B publication Critical patent/CN106714556B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
CN201580028014.7A 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统 Active CN106714556B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110060437.4A CN113009122B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461978773P 2014-04-11 2014-04-11
US61/978,773 2014-04-11
US201462002169P 2014-05-22 2014-05-22
US62/002,169 2014-05-22
US14/493,141 US20150294081A1 (en) 2014-04-11 2014-09-22 Methods and systems for determining autism spectrum disorder risk
US14/493,141 2014-09-22
US14/633,558 2015-02-27
US14/633,558 US9176113B1 (en) 2014-04-11 2015-02-27 Methods and systems for determining autism spectrum disorder risk
PCT/US2015/025247 WO2015157601A1 (en) 2014-04-11 2015-04-10 Methods and systems for determining autism spectrum disorder risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110060437.4A Division CN113009122B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Publications (2)

Publication Number Publication Date
CN106714556A CN106714556A (zh) 2017-05-24
CN106714556B true CN106714556B (zh) 2021-01-26

Family

ID=54264902

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110060437.4A Active CN113009122B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统
CN201580028014.7A Active CN106714556B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110060437.4A Active CN113009122B (zh) 2014-04-11 2015-04-10 用于测定自闭症谱系病症风险的方法和系统

Country Status (6)

Country Link
US (3) US9176113B1 (enExample)
EP (2) EP3151665B1 (enExample)
JP (5) JP6550124B2 (enExample)
CN (2) CN113009122B (enExample)
CA (3) CA2945528C (enExample)
WO (1) WO2015157601A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
MX388989B (es) * 2015-01-09 2025-03-11 Global Genomics Group Llc Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerótica.
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
KR102358879B1 (ko) 2015-05-22 2022-02-08 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
WO2017197252A1 (en) * 2016-05-13 2017-11-16 Stemina Biomarker Discovery, Inc. Autism subsets
US20200061127A1 (en) * 2016-11-11 2020-02-27 Arizona Board Of Regents On Behalf Of Arizona State University Methods and Compositions for Changing Metabolite Levels in a Subject
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US12025596B2 (en) 2018-02-19 2024-07-02 The Regents Of The University Of Colorado, A Body Corporate 6-oxo-pipecolic acid quantitation by mass spectrometry
US20220050090A1 (en) * 2018-09-11 2022-02-17 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of microbiota related metabolites
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
WO2020206447A2 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for maternal risk of having a child with autism spectrum disorder
US20220163538A1 (en) * 2019-04-05 2022-05-26 Arizona Board Of Regents On Behalf Of Arizona State University Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms
CA3138346A1 (en) * 2019-05-31 2020-12-03 Metabolon, Inc. Mass spectrometry assay methods for detection of metabolites
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
CN112180005B (zh) * 2020-09-01 2022-10-04 上海市疾病预防控制中心 一种预测鉴定生物样本中酰基肉碱的方法及其应用
EP4214504A4 (en) * 2020-09-21 2025-03-12 Molecular You Corporation METHOD OF DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER
CN113539478B (zh) * 2021-06-24 2023-04-07 山西医科大学 基于代谢组学的深静脉血栓形成预测模型的建立方法
CN115938490B (zh) * 2023-03-07 2023-06-06 之江实验室 一种基于图表示学习算法的代谢物鉴定方法、系统和设备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
CN101802607A (zh) * 2007-07-26 2010-08-11 菲诺梅诺米发现公司 用于诊断、风险评价、和监测孤独症谱系病症的方法
CN102576022A (zh) * 2009-08-14 2012-07-11 加利福尼亚大学董事会 诊断和治疗自闭症的方法
CN104768560A (zh) * 2012-08-29 2015-07-08 加州理工学院 孤独症谱系障碍的诊断和治疗

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
WO2004088309A2 (en) 2003-03-28 2004-10-14 Cantata Laboratories, Inc. Methods for diagnosing urinary tract and prostatic disorders
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
WO2008021515A2 (en) 2006-08-18 2008-02-21 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
WO2009151967A1 (en) 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
GB0912685D0 (en) * 2009-07-22 2009-08-26 Imp Innovations Ltd Methods
AU2011248464B2 (en) 2010-04-29 2016-08-11 Stemina Biomarker Discovery, Inc. Metabolic biomarkers of autism
KR20140140069A (ko) * 2012-03-05 2014-12-08 버그 엘엘씨 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
AU2013229381A1 (en) 2012-03-09 2014-09-25 Integragen A genotyping test for assessing risk of autism
US20140045702A1 (en) * 2012-08-13 2014-02-13 Synapdx Corporation Systems and methods for distinguishing between autism spectrum disorders (asd) and non-asd development delay

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
CN101802607A (zh) * 2007-07-26 2010-08-11 菲诺梅诺米发现公司 用于诊断、风险评价、和监测孤独症谱系病症的方法
CN102576022A (zh) * 2009-08-14 2012-07-11 加利福尼亚大学董事会 诊断和治疗自闭症的方法
CN104768560A (zh) * 2012-08-29 2015-07-08 加州理工学院 孤独症谱系障碍的诊断和治疗

Also Published As

Publication number Publication date
US20240019417A1 (en) 2024-01-18
WO2015157601A1 (en) 2015-10-15
EP3151665B1 (en) 2021-03-10
JP2023178345A (ja) 2023-12-14
US9176113B1 (en) 2015-11-03
CN106714556A (zh) 2017-05-24
JP2017510821A (ja) 2017-04-13
EP3151665A1 (en) 2017-04-12
US20160091481A1 (en) 2016-03-31
EP3954991A2 (en) 2022-02-16
CA3030255C (en) 2022-07-05
CA2945528A1 (en) 2015-10-15
JP2025172836A (ja) 2025-11-26
CA3157221A1 (en) 2015-10-15
CN113009122B (zh) 2025-01-17
JP2019200210A (ja) 2019-11-21
JP2021103177A (ja) 2021-07-15
EP3151665A4 (en) 2018-04-25
EP3954991A3 (en) 2022-05-18
JP6550124B2 (ja) 2019-07-24
CA2945528C (en) 2019-03-12
US20150293072A1 (en) 2015-10-15
CN113009122A (zh) 2021-06-22
CA3030255A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
CN106714556B (zh) 用于测定自闭症谱系病症风险的方法和系统
US20240230622A9 (en) Methods and Systems for Determining Autism Spectrum Disorder Risk
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Liang et al. Metabolomics of alcoholic liver disease: a clinical discovery study
US20150212098A1 (en) Diagnostic assay for alzheimer's disease
Laila et al. Role of proteomics in the discovery of autism biomarkers
US20170059581A1 (en) Methods for diagnosis and prognosis of inflammatory bowel disease using cytokine profiles
Liang et al. Novel liquid chromatography-mass spectrometry for metabolite biomarkers of acute lung injury disease
CN115684451A (zh) 基于代谢组学的食管鳞癌淋巴结转移诊断标志物及其应用
CN115440375A (zh) 一种结直肠癌预测系统及其应用
CN110396538B (zh) 偏头痛生物标志物及其用途
CN115436633B (zh) 一种结直肠癌检测的生物标志物及其应用
HK40051641A (zh) 用於测定自闭症谱系病症风险的方法和系统
WO2007139777A2 (en) Methods for the diagnosis and prognosis of alzheimer's disease using csf protein profiling
HK40065445A (en) Methods and systems for determining autism spectrum disorder risk
De Sota et al. Transcriptome profiling of cerebrospinal fluid in Alzheimer’s Disease reveals molecular dysregulations associated with disease
US20230402131A1 (en) Biomarker and diagnosis system for colorectal cancer detection
Smith et al. Maximizing Analytical Performance in Biomolecular Discovery with LC-MS: Focus on Psychiatric Disorders
CN116804676A (zh) 一种与哮喘相关的生物标志物及其应用
CN118777615A (zh) 生物标记物和其组合在制备用于ards诊断和预后评估的产品中的应用
CN121141918A (zh) 代谢标志物的检测试剂在制备肝病诊断产品中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant